HSD17B13 and metabolic dysfunction-associated steatotic liver disease: In contrast to variants that increase MASLD risk, recent studies have identified two novel protective variants in the HSD17B13 (rs72613567 T>TA; 17-β hydroxysteroid dehydrogenase 13) and MTARC1 (rs2642438 G>A p.Ala165Thr; mitochondrial amidoxime reducing component 1) genes that are linked to lower risk of MASLD [10,11,12,13,14].